Antitumor efficacy data in various mouse models and ex vivo analysis data have suggested that STA551 binds selectively to CD137 in tumors, but quantitative detection of conventional and switch antibody biodistribution in tumor and normal tissues under physiological conditions has been a challenge7. The gene discussed is TNFRSF9; the disease is neoplasm.